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E-mail address: rik.derynck@ucsf.edu (R. Derynck)TGF-b family signaling through Smads is conceptually a simple and linear signaling pathway, driven
by sequential phosphorylation, with type II receptors activating type I receptors, which in turn acti-
vate R-Smads. Nevertheless, TGF-b family proteins induce highly complex programs of gene expres-
sion responses that are extensively regulated, and depend on the physiological context of the cells.
Regulation of TGF-b signaling occurs at multiple levels, including TGF-b activation, formation, acti-
vation and destruction of functional TGF-b receptor complexes, activation and degradation of
Smads, and formation of Smad transcription complexes at regulatory gene sequences that cooperate
with a diverse set of DNA binding transcription factors and coregulators. Here we discuss recent
insights into the roles of post-translational modiﬁcations and molecular interaction networks in
the functions of receptors and Smads in TGF-b signal responses. These layers of regulation demon-
strate how a simple signaling system can be coopted to exert exquisitely regulated, complex
responses.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The TGF-b family of secreted proteins is encoded by 33 genes for
structurally related polypeptides marked by a signal peptide, a
large pro-domain and a C-terminal mature polypeptide that is
characterized by its spacing of seven or nine cysteines [1]. The
mature polypeptides form disulﬁde-bonded dimers, which have
primarily been studied as homodimers, yet also form physiological
heterodimers with potent biological activities. Among the TGF-b
family proteins, TGF-b1 has served as preferred model and proto-
type to study mechanisms of ligand-induced receptor activation
and signaling mechanisms that are activated by the TGF-b family
proteins.
TGF-b family proteins are involved in a large variety of processes
in all metazoans, in both development and tissue physiology, and
the deregulation of their activities is at the basis of many diseases.chemical Societies. Published by E
f Cell and Tissue Biology,
al Center Way, Room RMB-
.Most TGF-b proteins regulate cell proliferation and cell differentia-
tion programs. Additionally, activins, bone morphogenetic proteins
(BMPs) and growth and differentiation factors (GDFs) are perhaps
best known for their key roles in cell and tissue differentiation,
andmorphogenesis. Activins also playmajor roles in hormonal con-
trol and homeostasis, and TGF-b controls differentiation and func-
tion of hematopoietic and immune cells. While deregulation of
BMP signaling can lead to many developmental syndromes, i-
ncreased TGF-b1 expression and activities are known to drive can-
cer progression and ﬁbrosis in many tissues. These and other
observations illustrate the pervasive involvement of TGF-b family
proteins in a plethora of biological processes and physiological con-
texts [2].
2. TGF-b signaling through cell surface receptor complexes and
Smads
TGF-b family proteins initiate intracellular signaling by binding
to tetrameric cell surface complexes of two pairs of transmem-
brane kinases, the type II and the type I receptors (Fig. 1). Cytoplas-
mic receptor phosphorylation upon TGF-b ligand binding thenlsevier B.V. All rights reserved.
Fig. 1. Regulation of the TGF-b receptors. The TGF-b signaling pathway is outlined in thick gray lines, whereas the endosomal recycling pathway and lipid rafts-caveolae
degradation pathway are indicated by green and blue lines, respectively. Binding of ligand stabilizes the heteromeric complex of TbRII and TbRI receptors, resulting in
activation of TbRI through phosphorylation of its GS domain by TbRII. R-Smads are then activated by TbRI with SARA as scaffold, and form trimeric complexes with Smad4
that translocate into the nucleus, where they direct transcription responses of target genes. Activated receptor complexes are also internalized through lipid rafts and
caveolae, where they are poly-ubiquitylated by E3 ubiquitin ligases recruited by Smad7 and destined for degradation. Various regulators of functional TGF-b receptor
complexes are schematically shown. Inhibitory mechanisms are listed in a red box with blunt-headed lines, whereas those that enhance the complexes formation are listed in
a green box with arrows.
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Viewing TGF-b as prototype, ligand binding stabilizes the interac-
tion of TbRII dimers with two TbRI molecules, enabling the TbRII
kinases to phosphorylate the short juxtamembrane, glycine- and
serine-rich GS domains of the TbRI receptors on serines and threo-
nines [3]. Their phosphorylation then triggers conformational
changes in TbRI that activate the TbRI receptor kinase [4], concom-
itantly with the release of the immunophilin inhibitor FKBP12 that
associates with the unliganded TbRI receptor and helps maintain it
in a silenced state [4,5]. The phosphorylated GS domain of the acti-
vated TbRI also provides the type I receptors with a surface to
interact with the basic patch of the MH2 domains of Smad2 and
Smad3 [4,6], which will serve as signaling effectors of TGF-b. The
Smad–TbRI interaction, presumably in a 2:2 stoichiometry, allows
the TbRI kinase to phosphorylate the Smad on two serines within
its conserved C-terminal –SSXS motif. Upon phosphorylation, the
charged C-terminal sequence of the receptor-activated Smad
(R-Smad) can then intramolecularly interact with its basic patch,
thus weakening R-Smad binding to TbRI, and enabling the release
of the activated R-Smad from TbRI [6,7]. A similar mechanism may
allow BMP-induced activation of Smad1 and Smad5 by BMP type I
receptors. Binding of TGF-b or TGF-b-related factors to their cog-
nate receptor complexes also results in activation of non-Smad sig-naling pathways, such as MAP kinase pathways and the PI3K-Akt-
TOR pathway [8]. Activation of these non-Smad signaling path-
ways by TGF-b will not be discussed here.
Subsequently partnered with one Smad4 molecule, two acti-
vated R-Smads rapidly translocate into the nucleus as trimeric
complexes, where they elicit transcription responses on target
genes by associating with high afﬁnity DNA binding transcription
factors and conducive Smad binding DNA sequences at regulatory
promoter sequences (Fig. 2). Activated Smad complexes have been
shown to associate with, and regulate the activities of, a large vari-
ety of DNA binding transcription factors. Additional recruitment of
coactivators and corepressors further deﬁnes the TGF-b-induced
transcription activation or repression of target genes. The associa-
tion of R-Smads with the coactivators CBP or p300 often allows for
enhanced transcription activation, while also conferring histone
acetylation. Conversely, R-Smads have also been shown to recruit
histone deacetylases, leading to transcription repression and
histone deacetylation. The interactions of the activated Smad com-
plexes with divergent DNA-binding transcription factors, coactiva-
tors and corepressors allow for multiple types of functional
crosstalk between TGF-b/Smad signaling and other signaling path-
ways, since many of the Smad interaction partners are usually also
targeted by signaling pathways [9,10].
Fig. 2. Regulation of Smad signaling. Thick gray lines illustrate Smad signaling, whereas nucleocytoplasmic shuttling and degradation of Smads are indicated by solid and
dashed light-blue lines, respectively. Activation of R-Smads by TbRI facilitates the formation of trimeric R-Smad/Smad4 complexes, which are imported into the nucleus to
regulate transcription of target genes. R-Smad phosphorylation at various sites besides the C-terminus prevents nuclear import of the complexes, or favors degradation of the
complexes, resulting in termination of signaling. Diverse regulators modulate the activated Smad complexes inside the nucleus, and control the balance between complex
formation and dissociation, thus determining the overall signaling outcome in a context-dependent manner. Inhibitory mechanisms are listed in a red box with blunt-headed
lines, and those that promote the indicated processes are listed in a green box with arrows.
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the TGF-b receptors (Fig. 1) and Smads (Fig. 2) by post-transla-
tional modiﬁcations, often resulting from signaling crosstalk. We
will not elaborate on the signaling crosstalk that targets the many
transcription factors that associate with Smads at the DNA, and
thus regulates the transcriptional cooperativity.
3. Activation of latent TGF-b regulates TGF-b receptor signaling
The three TGF-bs, TGF-b1, -b2 and -b3 are secreted by most cell
types as latent complexes, consisting of the mature TGF-b dimer in
a non-covalent association with a dimer of the large pro-peptide,
i.e. the sequence preceding the mature monomer in the TGF-b pre-
cursor, and, covalently attached to this pro-peptide, a latent TGF-b
binding protein (LTBP). The latency of the TGF-b complex allows
for storage of TGF-b in association with extracellular matrixproteins without inadvertent activation of TGF-b signaling, and re-
quires an activation process to release biologically active TGF-b
that only then can bind and activate the TGF-b receptors [11,12].
Various mechanisms lead to latent TGF-b activation, with the mode
of TGF-b activation likely dependent on the cell type and physio-
logical context. Generally, activation of TGF-b occurs through the
actions of proteases, such as matrix metalloproteases (MMPs),
plasmin, and thrombin that target LTBP, allowing release from
the latent complexes in the extracellular matrix [11,12].
Increasing evidence highlights key roles of integrins, speciﬁcally
avb6 and avb8 dimers, in latent TGF-b activation and TGF-b signal-
ing [13]. The pro-region of TGF-b1 comprises an RGD sequence that
is recognized by several integrin combinations, and this interaction
is thought to be essential for integrin-mediated activation of TGF-b.
Mice that express the TGF-b1 precursor with an inactivated RGD
sequence show a phenotype that strongly resembles that of
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activation. Consistent with this notion, conditional loss of integrin
avb8 expression in dendritic cells causes severe inﬂammatory bo-
wel disease and age-related autoimmunity in mice, presumably
resulting from the absence of TGF-b activity and failure of regula-
tory T cell induction [15,16].
Integrin avb8-mediated activation of TGF-b appears to involve
proteolytic cleavage, e.g. through the metalloproteases MT1-MMP,
also called MMP14 [17]. In contrast, avb6-mediated activation of
TGF-b1 may occur without participation of a protease and involve
a conformation change that results in TGF-b activation [18,19].
Furthermore, myoﬁbroblast contraction leads to activation of
TGF-b1 from extracellular matrix stores, through a process that
requires integrins [19]. Additionally, TGF-b released from platelets
or ﬁbroblasts is activated in response to shear stress [20], illustrat-
ing the importance of force-catalyzed release of TGF-b ligands.
4. Regulation of TGF-b receptor signaling by microRNAs
MicroRNAs (miRNAs) are small non-coding RNAs that speciﬁ-
cally bind target mRNAs and inhibit mRNA translation or promote
mRNA degradation [21]. MicroRNAs are increasingly seen as dy-
namic regulators of signaling pathways, by controlling levels of
key components of these pathways [22]. Several miRNAs directly
target the mRNAs encoding TbRII, or the type II Nodal receptor.
These include the miR-302/367 cluster, miR-372, miR-520/373,
miR-17–92 cluster, miR-15, and miR-16 [23–27]. Since they are
capable of inhibiting TGF-b receptor expression, and the receptor
levels correlate with TGF-b responsiveness [28,29], these miRNAs
control the threshold for signaling initiation in response to TGF-b
or TGF-b-related factors [23–27]. Additional components for each
step of the TGF-b signaling cascade may also be modulated by spe-
ciﬁc miRNAs, raising the possibility of a previously unanticipated,
complex and context-dependent miRNA network controlling
TGF-b signaling.
5. Control of TGF-b receptor availability through ectodomain
shedding
The cell surface levels of TGF-b receptors, and, consequently, the
sensitivity of cells to TGF-b, are controlled by ectodomain shed-
ding. TACE, a transmembrane ADAMmetalloproteinase also known
as ADAM17, proteolytically removes the ectodomain of TbRI, but
not TbRII [29], and this process is facilitated by TRAF6-mediated
TbRI ubiquitylation [30]. TACE-mediated ectodomain shedding is
activated in response to ERK or p38 MAPK pathway signaling
[29,31]. Activation of either pathway by growth factors or inﬂam-
matory signals consequently decreases cell surface levels of TbRI,
but not TbRII, thus attenuating TGF-b-induced Smad3 activation
without affecting TGF-b binding to the cell surface TbRII receptors
[29]. Conversely, inhibition of TACE increases the cell surface TbRI
level, Smad3 activation, and TGF-b-induced cytostasis and epithe-
lial–mesenchymal transition [29]. Downregulation of TGF-b signal-
ing through TACE activation in response to growth stimulatory or
inﬂammatory cues provides a strategy for evasion of autocrine
tumor suppression by TGF-b, and for modulation of epithelial-mes-
enchymal transition in cancer progression [29,31]. Upon release of
the TbRI ectodomain, the TbRI cytoplasmic domain can be released
from the plasma membrane, translocates into the nucleus, and
then acts as a transcription factor in potentiating the expression
of Snail and MMP2 [30].
Another ADAMmetalloproteinase, ADAM12, was shown to form
a complex with the type II TGF-b receptor, and facilitate activation
of TGF-b signaling through a mechanism independent of its prote-
ase activity. ADAM12 also induces TbRII accumulation in earlyendosomal vesicles and stabilizes TbRII, and was proposed to do
so by suppressing the association of TbRII with Smad7 [32].
6. TGF-b receptor phosphorylation and dephosphorylation
Receptor phosphorylation provides the basis for signal trans-
duction in response to TGF-b. TGF-b binding stabilizes the TbRII–
TbRI interactions, enabling TbRII to phosphorylate the GS domain
of TbRI on serines and threonines. The resulting conformational
change in TbRI then activates the TbRI kinase, which then initiates
Smad and non-Smad signaling [4]. TGF-b binding to the receptor
complex also induces TbRI phosphorylation outside its GS domain,
presumably by TbRII and through autophosphorylation upon TbRI
activation. The identities, functions, and mechanism of phosphory-
lation of these sites remain to be deﬁned [33]. The phosphorylation
status of TbRII also remains largely uncharacterized, and TbRII
phosphorylation may similarly combine autophosphorylation and
phosphorylation by TbRI. Whether additional kinases can phos-
phorylate TbRI or TbRII on serine or threonine also remains to be
determined.
The TbRI and TbRII receptors are additionally phosphorylated
on tyrosines. TbRII and TbRI are both dual speciﬁcity kinases,
which are characterized by strong serine and threonine but weaker
tyrosine phosphorylation capacities [34]. Their dual speciﬁcities
are consistent with structural features in their sequences that
phylogenetically place TbRII, TbRI and the other type I and type II
TGF-b family receptors between tyrosine and serine-threonine
kinases, and close to other dual speciﬁcity kinases [35]. TbRII phos-
phorylation on tyrosine may result from autophosphorylation [36],
although TbRII can also be phosphorylated by the tyrosine kinase
Src [37]. Phosphorylation by Src enables TbRII to recruit Grb2
and Shc, contributing to the TGF-b-induced activation of p38 MAPK
[37]. TGF-b also induces tyrosine phosphorylation of TbRI, resulting
from autophosphorylation or mediated by TbRII [38]. TbRI phos-
phorylation on Tyr may play a role in TGF-b-induced activation
of Erk MAPK signaling, which is initiated by Shc association with
TbRI through its phosphoTyr-binding SH2 and PTB domains resi-
dues, and subsequent Shc phosphorylation on Tyr by TbRI [38].
The activation state of the TGF-b receptors is also regulated by
dephosphorylation [39]. Smad7 was shown to interact with
GADD34, a regulatory subunit of the protein phosphatase 1 (PP1)
holoenzyme, and thus recruit the catalytic subunit of PP1 (PP1c)
to TbRI, resulting in TbRI dephosphorylation and inhibition of
TGF-b-induced cell cycle arrest [40]. Additionally, SARA, an endo-
somal adaptor protein that associates with TbRI, may also target
PP1c to Drosophila receptor complexes that are activated by the
BMP ortholog Dpp. In this way, PP1c can attenuate Dpp signaling
through dephosphorylation of the type I receptor, Tkv [41]. Finally,
regulatory subunits of protein phosphatase 2A (PP2A) also associ-
ate with TGF-b receptors and regulate their activity [42,43]. Sur-
prisingly, the regulatory Ba and Bd subunits modulate TGF-b/
Activin/Nodal signaling in opposite ways. The Ba subunit of PP2A
enhances the cytostasis effect of TGF-b [42,43], whereas Bd is
thought to negatively modulate these responses by restricting
the receptor activity [42].
7. Ubiquitylation and sumoylation of the TGF-b receptor
Ubiquitylation, i.e. the covalent attachment of ubiquitin poly-
peptides, and ubiquitin-mediated protein degradation deﬁne the
levels and turnover of proteins in a wide range of processes. Ubiq-
uitylation results from sequential actions of E1, E2 and E3 ubiquitin
ligases that provide substrate speciﬁcity [44]. The stability and
levels of TGF-b receptor complexes are determined by ubiquityla-
tion. Speciﬁcally, Smad7 recruits, through direct association, an
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degradation [45]. Multiple E3 ligases were shown to be involved
in TbRI ubiquitylation, including the HECT-type ligases Smurf1,
Smurf2, WWP1, and NEDD4–2, which associates with the E2 ligase
UbcH7 and an N-terminal sequence in Smad7 [45–48]. The contri-
butions of the individual E3 ligases to the regulation of the TGF-b
receptors in vivo remain to be fully characterized.
Conversely, the deubiquitylating enzyme USP15 was shown to
associate with the Smad7–Smurf2 complex, and to deubiquitylate
and stabilize TbRI, leading to enhanced TGF-b signaling in glioblas-
toma, breast and ovarian cancer [49]. Similarly to USP15, another
deubiquitylating enzyme, UCH37, forms a complex with Smad7
by binding to a sequence that is distinct from the PY motif with
which Smurf1 or Smurf2 interact, and also deubiquitylates and sta-
bilizes TbRI [50]. Finally, the 90-kD heat shock protein HSP90 was
reported to associate with TbRI and TbRII, and thus prevent
Smurf2-mediated receptor ubiquitylation and degradation [51].
Through a sequential process similar to ubiquitylation, sumoy-
lation covalently attaches a SUMO polypeptide that resembles
ubiquitin to its substrate. Sumoylation does not lead to degrada-
tion of the targeted protein, occurs primarily on perinuclear and
nuclear proteins, including transcription factors, and often regu-
lates subcellular localization and functions [44]. The TbRI receptor
is sumoylated at one deﬁned lysine residue in response to TGF-b.
TbRI sumoylation requires the kinase activities of TbRI and TbRII,
indicating that phosphorylation and possibly a conformational
change of TbRI are required for docking of the E3 ligase. Sumoyla-
tion of TbRI stabilizes the Smad2/3 binding to the TbRI receptor,
leading to enhanced Smad activation. Accordingly, lack of TbRI
sumoylation decreases TGF-b-induced Smad2 and Smad3 activa-
tion, and TGF-b-induced transcription of target genes [52].8. Endocytic routing of receptors
The endocytic routing of TGF-b receptors relies on constitutive
receptor internalization and recycling through either clathrin- or
caveolin-1-mediated endocytosis [53–55]. Through a di-leucine
internalizationmotif in the TbRII cytoplasmic domain, TGF-b recep-
tor complexes are internalized in clathrin-coated pits, and enter
EEA-1- and Rab5-positive early endosomes, which are recycled to
the cell surface in a manner that depends on the GTPase Rab11
[54,56]. In clathrin-coated pits, the association of the adaptor pro-
tein b2-adaptin with the cytoplasmic domain of TbRII couples the
TGF-b receptor complexes to the AP-2 subunit of clathrin [57].
TGF-b receptor internalization through clathrin-coated endosomes
is thought to be essential for Smad activation, since inhibition of
this endocytosis-recycling pathway prevents Smad activation
[54,56]. TbRII, TbRI and the adaptor protein SARA, which stabilizes
the TbRI–Smad interaction, are enriched in EEA-1-positive early
endosomes, and this localization is required for Smad2/3 activation
[58]. RIN1, a guanine nucleotide exchange factor of Rab5, promotes
TGF-b/Smad signaling by enhancing endocytosis [59].
In contrast to clathrin-mediated endocytosis, caveolin-1- and
lipid-raft-dependent endocytosis is thought to direct the TGF-b
receptors to degradation. Caveolin-1 interacts with TbRI as well as
Smad7 and Smurf2, which ubiquitylates TbRI, and inhibits TGF-b-
induced Smad signaling [54,60]. Silencing the expression of
caveolin-1 enhances the half-life of the TGF-b receptors and the
responsiveness of T-cells to TGF-b stimulation, whereas caveolin-
1 overexpression suppresses TGF-b-induced Smad signaling [61].
Other ﬁndings, however, argue for TGF-b-induced Smad activation
in both lipid rafts and non-lipid rafts, and for receptor degradation
in clathrin-mediated endocytosis [56]. Therefore, the exclusive
association of TGF-b-induced Smad activation and TGF-b receptor
degradation with clathrin-mediated versus caveolin-1-mediatedendocytosis, respectively, may not be unambiguous as sometimes
believed. Interestingly, TGF-b-induced MAPK activation may re-
quire the presence of TGF-b receptors in lipid rafts [62]. Distinct
internalization routes may confer different signaling capabilities
of TGF-b receptor.
In addition to Rab5 and Rab11, other GTPases have been impli-
cated in directing TGF-b receptor endocytosis and recycling [63].
For instance, Rap2 competes with Smad7 for binding to TbRI, and
directs internalized receptor complexes to the recycling pathway
to prevent their degradation, thus delaying receptor turnover,
and contributing to upregulation of Smad activation [64].
9. Other TGF-b receptor interacting proteins
Since the identiﬁcation of the TbRI and TbRII receptors, a stea-
dily increasing number of proteins were shown to associate with
TGF-b receptors and function as modulators of TGF-b signaling
(Fig. 1). This diversity of interacting proteins reﬂects the dynamic
changes in the life cycle of the receptors, ranging from maturation
and cell surface transport of newly synthesized TbRI and TbRII, to
deﬁning their subcellular localization, cell surface presentation
and ligand binding, differential endosomal and intracellular rout-
ing, Smad accessibility and differential activation of Smad and
non-Smad pathways, and receptor stability and degradation. These
proteins are listed in Tables 1 and 2 with a brief description of their
actions. The extensive and complex regulation of the TGF-b recep-
tors through protein associations and post-translational modiﬁca-
tions allows for a highly regulated and ﬁnely tuned receptor
signaling system that deﬁnes the TGF-b responsiveness of the cells
and differential regulation of TGF-b responses (Fig. 1).
10. Regulation of receptor-activated Smad function by
phosphorylation
Among the eight Smads in vertebrates, Smad2 and Smad3 are
activated in response to TGF-b, nodals, and activins, and Smad1,
Smad5 and Smad8 respond to BMPs and GDFs [65]. Once activated
by type I receptors, R-Smads form complexes of two R-Smads and
one Smad4, and translocate into the nucleus where they activate or
repress transcription of target genes (Figs. 1 and 2). These Smads
are characterized by a highly conserved N-terminal MH1 and C-
terminal MH2 domain, separated by a variable serine and pro-
line-rich linker region [2,6].
R-Smad activation results from ligand-induced phosphorylation
of the C-terminal two serines in their –SSXS motif by type I recep-
tors. However, the linker region can also be phosphorylated on Ser
or Thr by other kinases, e.g. Erk MAPK and CDK kinases, which con-
sequently control Smad activities [8,10]. Considering the ﬂexible
nature of the Smad linker domains, different patterns of linker
phosphorylation are likely to impose conformation differences that
then affect protein interactions and Smad functions and stability.
Recent insights illustrate an extensive control of Smad function
by linker phosphorylation. For less recent ﬁndings, we refer to an
excellent review on regulation of Smad function by phosphoryla-
tion [39].
Besides the rapid activation of Smad3 through C-terminal phos-
phorylation, TGF-b induces linker phosphorylation at three sites in
Smad2 and Smad3, albeit with slower kinetics. This phosphoryla-
tion is mediated by GSK3, also a downstream effector of Wnt sig-
naling, or CDK8 and CDK9 [66–68], and marks activated Smad2
or Smad3 for proteasomal destruction. The E3 ubiquitin ligase
Nedd4L then recognizes the phosphoT-P-Y motif in the linker,
leading to Smad2/3 polyubiquitylation and degradation [69], limit-
ing the half-life of activated Smads and, consequently, the ampli-
tude and duration of TGF-b responses. CDK8 and CDK9 also
Table 2
TGF-b receptor-interacting proteins that attenuate TGF-b signaling.
Interacting
protein
Regulatory mechanism References
Smad7 Competing with recruitment of R-Smads to TbRI receptor, and preventing R-Smad activation;
Recruiting ubiquitin E3 ligases such as Smurf2, WWP1 and SIK to TbRI receptor to degrade receptors;
Recruiting subunit of phosphatase such as GADD34-PP1c to dephosphorylate TbRI
[40,45,48,133,184]
FKBP12 Binding to GS domain of TbRI to prevent leaky signaling;
Interacting with Smad7 and TbRI to form a complex with Smurf1 to degrade TbRI
[4,185]
TMEPAI Interacting with R-Smads to compete for association with the TbRI receptor [186]
Dpr2 Binding to TbRI receptor to promote its lysosomal degradation [187,188]
Rock2 Binding to TbRI and accelerating its lysosomal degradation [189]
STRAP Interacting with TbRI and TbRII receptors and stabilizing Smad7:receptor complexes [190]
SIK Associating with Smad7, TbRI, and Smurf2 to form a complex to degrade TbRI [184,191]
PDK1 Interacting with STRAP and enhancing STRAP-induced inhibition [192]
BAMBI Interfering with TbRI and TbRII complex formation, and forming a ternary complex with activated TbRI and Smad7 to prevent
Smad association
[193,194]
ALK1 Associating with TbRI and TbRII to form a complex and antagonize Smad2/3 activation [195]
Itch/AIP4 Enhancing TbRI:Smad7 association and inhibiting Smad activation [196]
UbcH7 Serving as ubiquitin-conjugating enzyme (E2) to facilitate TbRI degradation by Smurf2 [46]
YAP-65 Augmenting the association of Smad7 to activated TbRI and inhibiting Smad activation [197]
c-Ski Associating with activated TbRI, resulting in constitutive association of TbRI with non-functional R-Smad/Smad4 complexes [198]
TrkC Binding to TbRII and preventing it from interacting with TbRI, and blocking Smad activation [199]
Tctex2b Interacting with TbRII and inhibiting TGF-b signaling [200]
ETV6-NTRK3 Directly binding to TbRII and preventing it from interacting with TbRI [201]
Table 1
TGF-b receptor-interacting proteins that potentiate TGF-b signaling.
Interacting protein Regulatory mechanism References
SARA Stabilizing R-Smads and TGF-b receptor association;
Directing the activated receptor towards clathrin-mediated endocytic routing
[58,165,166]
Hgs Cooperating with SARA to stabilize TGF-b receptor:R-Smad association [167]
cPML Interacting with R-Smads and SARA to improve their association;
Improving TGF-b receptor and SARA accumulation in early endosomes
[168]
Axin Adapter of Smad3 to facilitate its activation by TbRI;
Forming a multimeric complex consisting of Smad7 and Arkadia to degrade Smad7
[74,145,153]
Dab2 Associating with both TGF-b receptors and R-Smads to facilitate R-Smad activation;
Promoting clathrin-mediated recycling of TbRII to protect it from degradation
[169,170]
TbRIII/betaglycan Mediating Smad-independent activation of TRAF6-TAK1-p38 MAPK with TbRI [171]
VE-cadherin Enhancing TbRII:TbRI assembly into an active receptor complex to improve R-Smad phosphorylation [172]
Occludin Regulating TbRI localization to enhance Smad activation [173]
TRAF6 Mediating the activation of p38 and JNK MAPK by ubiqitylation and phosphorylation of TAK1;
Inhibiting TGF-b-induced R-Smad activation and IL-2 blockage in T cells
[174–176]
Integrin avb3 Interacting with TbRII to potentiate TGF-b1 activation [177]
HSP90 Binding to TbRI and TbRII to prevent Smurf2-mediated receptor ubiquitylation and degradation [51]
Itch/AIP4 Facilitating TGF-b receptor-Smad2 complex formation and enhancing TGF-b induced transcription [91]
CD44 Associating with TbRI to promote Smad2/3 activation and PTH-rP expression [178]
Mgat5 Modifying N-glycans on TGF-b receptors to delay their removal at the cell surface by constitutive endocytosis [179]
TLP Associating with TbRI and TbRII to regulate the balance of Smad2 and Smad3 signaling by localizing Smad4 intracellularly [180]
BAT3 Interacting with TbRI and TbRII to potentiate Smad activation [181]
km23–1 Associating with TGF-b receptors and Smad2 in early endosomes to potentiate Smad activation [182]
xIAP Interacting with TbRI, mediating the activation of NF-jB by ubiquitiylation of TAK1, and coupling of Smad2/3 activation [183]
1876 P. Xu et al. / FEBS Letters 586 (2012) 1871–1884phosphorylate the linker region of Smad1, resulting in recruitment
of YAP, an effector of the Hippo pathway of cell size control. This
interaction enhances Smad-mediated transcription, although the
phosphorylated linker is ultimately recognized by the E3 ubiquitin
ligase Smurf1, leading to Smad degradation [68,70]. The duration
of Smad1 signaling is also regulated by sequential linker phosphor-
ylation at conserved MAPK and GSK3 sites, leading to polyubiqui-
tylation, and eventual transport to the centrosome for proteasomal
degradation [71]. Because Smad linker phosphorylation by CDK8 or
CDK9, and/or GSK3, results in recruitment of YAP and the peptidyl-
prolyl isomerase Pin1 for regulating transcription activity [70,72],
or Nedd4L or Smurf1 for R-Smad destruction [68], both processes
are coordinately regulated. The functional switch from initial Smad
activation to subsequent destruction appears to result from a
switch in recognition of Smad phosphoserines by WW domains
of both transcription factors and E3 ubiquitylating ligases [70].
For example, in the TGF-b pathway, Smad3 phosphorylation byCDK8/9 creates binding sites for WW domains of Pin1, and subse-
quent phosphorylation by GSK3 switches off Pin1 binding, and
adds binding sites for Smurf1 WW domains [70].
GRK2, a kinase involved in desensitizing G protein-coupled
receptors, also associates with R-Smads [73]. Phosphorylation of
R-Smad linker regions by GRK2 somehow inhibits ligand-induced
C-terminal phosphorylation, and prevents nuclear translocation
of Smad complexes, thus inhibiting TGF-b-induced target gene
expression. In this way, the induction of GRK2 expression in
response to TGF-b provides negative feedback to control TGF-b
responses. Non-activated Smad3 can also be phosphorylated in
its MH1 domain by GSK3-b in association with the scaffolding pro-
tein Axin. This phosphorylation results in Smad3 ubiquitylation
and degradation, and helps deﬁne the basal Smad3 level and activ-
ity (74].
Finally, it has been reported that the C-terminal –SSXS motif of
R-Smads can be targeted by kinases that are distinct from the type
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lates mitotic progression, can C-terminally phosphorylate and thus
activate Smad2 and Smad3 [75]. Additionally, the WNK family
kinase WNK1 [76] and MPK38 kinase [77] also directly activate
Smad2 and Smad3. The biological signiﬁcance of Smad activation
by these kinases needs to be further explored.
11. Dephosphorylation of receptor-activated Smads
Dephosphorylation of the C-terminal serines regulates the ter-
mination of Smad signaling. Among many phosphatases evaluated,
PPM1A/PP2Ca acts as Smad phosphatase for Smad2 and Smad3.
PPMA1 removes the receptor-mediated phosphorylation at the –
SSXS motif, and promotes nuclear export of TGF-b-activated
Smad2/3, thereby terminating TGF-b signaling [78]. The phospha-
tase PTEN, a negative regulator of the PI3K/Akt pathway, remark-
ably serves as co-factor of PPM1A, and helps abrogate Smad2/3
phosphorylation by stabilizing PPM1A [79]. The phosphatase
MTMR4 was also found to C-terminally dephosphorylate the acti-
vated Smad2 and Smad3 in endosomes [80]. Additionally, SCP
phosphatases remove the C-terminal phosphorylation of Smad1
and thus attenuate BMP signaling [81]. Under hypoxic conditions,
the phosphatase PP2A was shown to C-terminally dephosphorylate
Smad3, but not Smad2, suggesting a mechanism by which hypoxia
regulates growth factor responses [82]. Activated Smad2 or Smad3
dephosphorylation can be prevented by CLIC4, a multifunctional
protein that shuttles between the cytoplasm and nucleus. Nuclear
CLIC4 associates with activated Smad2 and Smad3, and protects
them from dephosphorylation [83]. Finally, the phosphatases
SCP1, SCP2 and SCP3 remove linker phosphorylation at certain
sites, without affecting C-terminal phosphorylation, of Smad2/3,
thus enhancing TGF-b signaling [84,85].
12. Ubiquitylation of R-Smads
TGF-b-induced Smad2 activation was shown to be followed by
poly-ubiquitylation and proteasomal degradation, thus targeting
nuclear Smad2 for degradation, and terminating its signaling
[86]. Since this initial observation, multiple ubiquitin ligases have
been implicated in R-Smad degradation, including Smurf1, Smurf2,
Nedd4–2, WWP1, ROC1-SCF, and CHIP [87]. As mentioned, TGF-b-
induced linker phosphorylation marks activated Smads for prote-
asomal destruction, and this involves the E3 ubiquitin ligase
Nedd4L [69]. Therefore, Nedd4L limits the half-life of TGF-b-acti-
vated Smads and restricts the intensity and duration of TGF-b sig-
naling. The E3 ubiquitin ligase Arkadia, which was initially shown
to ubiquitylate Smad7 and the Smad corepressor SnoN, and target
them for degradation [88], also ubiquitylates activated R-Smads,
causing their degradation [89]. Additionally, the estrogen receptor
was shown to form a complex with Smads, facilitating estrogen-
dependent recruitment of Smurf1 for subsequent R-Smad degrada-
tion [90].
In contrast to poly-ubiquitylation, which leads to degradation,
mono-ubiquitylation has different effects on Smad2 and Smad3
functions. The HECT-domain E3 ligase Itch/AIP4 can form a com-
plex with Smad2 and activated TbRI, resulting in Smad2 mono-
ubiquitylation, which in turn enhances the Smad2 interaction with
the receptor, and Smad2 activation [91]. Smad3 was shown to be
mono-ubiquitylated in its MH1 domain at multiple lysines, and
these modiﬁcations interfere with Smad3 binding to regulatory
promoter sequences [92]. The de-ubiquitylating enzyme USP15 op-
poses the MH1 domain mono-ubiquitylation, and thus enhances
the occupancy of target promoters by Smad complexes [92], sug-
gesting a dynamic balance of mono-ubiquitylation and de-ubiqui-
tylation in the control of R-Smad activities. Consequently, silencingUSP15 expression abolishes the recruitment of TGF-b-activated
Smad complexes to regulatory DNA sequences. Smad3 is addition-
ally mono-ubiquitylated at four lysine residues in the MH2 domain
through the action of the E3 ligase Smurf2 [93]. Rather than con-
trolling Smad3 stability through poly-ubiquitylation, Smurf2-med-
iated mono-ubiquitylation interferes with the formation of
functional Smad3 complexes. This mono-ubiquitylation requires
prior TGF-b-induced phosphorylation of Thr179 and adjacent PY
motif in the linker region by CDKs. Finally, the deubiquitylase CYLD
inhibits TGF-b signaling by decreasing the stability of Smad3. This
effect, however results from Akt de-ubiquitylation that relieves
Akt-mediated inhibition of GSK3b-CHIP-induced degradation of
Smad3 [94].
13. Acetylation and ADP-ribosylation of R-Smads
Resulting from their TGF-b-induced association in nucleopro-
tein complexes, Smad2 and Smad3 are acetylated by the coactiva-
tors CBP and p300 in response to TGF-b. Smad3 is acetylated in its
MH2 domain, whereas Smad2 is primarily acetylated in its MH1
domain, yet both acetylations enhance Smad-mediated transcrip-
tion [95–97]. Thus, coactivator-mediated acetylation of receptor-
activated Smad molecules in the nucleus may represent a novel
way to modulate TGF-b signaling.
Smad3 can also be ADP-ribosylated in its MH1 domain through
the action of poly(ADP-ribose) polymerase-1 (PARP-1), which asso-
ciates with these Smads. This modiﬁcation results in dissociation of
Smad complexes from DNA, and, thus, attenuation of Smad-medi-
ated TGF-b responses [98]. ADP-ribosylation of Smad proteins may
serve as an important step in controlling the intensity and duration
of Smad-mediated transcription.
14. Regulation of nucleo-cytoplasmic shuttling of R-Smads
The disparate subcellular sites of R-Smad activation by cell sur-
face TGF-b receptor complexes and their subsequent roles in tran-
scription regulation of target genes requires efﬁcient and highly
regulated nucleo-cytoplasmic shuttling [99]. This regulation in-
volves nuclear localization sequences (NLS) in R-Smads, and the
actions of importins b1, 7, 8 in nuclear import, and exportin 4
and Ran GTPases for nuclear export [100–102]. RanBP3, an inter-
acting partner of Ran, CRM1 and nucleopore components, is re-
quired for nuclear export of Smad2 and Smad3, as it directly
recognizes dephosphorylated Smad2 and Smad3, and facilitates
their nuclear export to terminate the TGF-b signaling [103]. Phos-
phorylation of R-Smads and Smad complex formation promote
their accumulation in the nucleus, while dephosphorylation by
Smad phosphatases favors nuclear export [78,81,104].
The nuclear import of Smad complexes is also regulated by Akt.
Attenuation of TGF-b-induced growth inhibition and apoptosis by
PI3K/Akt signaling may result from direct association of Akt with
unphosphorylated Smad3, thus preventing Smad3 activation,
complex formation with Smad4, nuclear translocation and Smad-
mediated transcription [105,106]. This function is thought to be
independent of the Akt kinase activity, and creates a scenario that
the Smad3 to Akt ratio correlates with the sensitivity of cells to
TGF-b [106]. Other evidence, however, suggests that the kinase
activity of Akt is required and that mTOR plays a role in suppress-
ing Smad3 activation and induction of apoptosis [107]. SnoN, a co-
repressor of Smad transcription complexes, which is predominant
in the cytoplasm, can retain Smad proteins in the cytoplasm
through its association with R-Smads. SnoN therefore represses
TGF-b signaling using a dual mechanism, by preventing nuclear
translocation of the Smad proteins, and as Smad corepressor at
promoters of target genes [108]. The Notch1 intracellular domain
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enhances its transcriptional activity, which may explain the
enhanced TGF-b-induced functional activation of regulatory T-cells
upon Notch signaling [109].
TAZ and YAP, transcription regulators in the Hippo pathway,
also play a key role in nuclear import of TGF-b-activated Smad
complexes and their recruitment to the Smad-binding DNA se-
quences. TAZ associates with Smad2/3-Smad4 complexes and is re-
quired for their nuclear import in embryonic stem cells, and is also
co-recruited to Smad-mediated transcription complexes [110]. At
high cell density, and in response to the formation of polarity com-
plexes, TAZ and YAP translocate into the cytoplasm and sequester
Smad complexes, thereby preventing nuclear translocation and
suppressing TGF-b signaling. During mouse embryogenesis, TAZ
and/or YAP phosphorylation drives their nuclear accumulation, as
well as that of Smad2/3 [111]. Therefore, TAZ and YAP deﬁne a
hierarchical system that regulates nuclear accumulation and tran-
scription functions of activated Smad complexes.
15. Post-translational regulation of Smad4
Upon TGF-b-induced activation, complexes of Smad2 and/or
Smad3 with Smad4 translocate into the nucleus. Smad4, however,
is not required for nuclear import of R-Smads [112]. Once incorpo-
rated in nucleoprotein complexes with DNA binding transcription
factors, Smad4 functions as transcription coactivator, thus enhanc-
ing the effectiveness of R-Smad-mediated transcription [113].
Although Smad4 is not essential for R-Smad mediated transcrip-
tion, cells that lack Smad4 generally exhibit much weaker target
gene responses [65]. Like the R-Smads, the functions of Smad4
are modulated by post-translational modiﬁcations that deﬁne the
interactions of Smad4 with other proteins, its subcellular localiza-
tion, and its stability (Fig. 2).
Similarly to other Smads, Smad4 shuttles between the cyto-
plasm and nucleus, with nuclear import and export mediated by
distinct nuclear localization and export sequences. Several impor-
tins and nuclear pore proteins, including CAN/Nup214, have been
implicated in nuclear import of Smad4 or heteromeric Smad com-
plexes [65,100]. Nuclear export of Smad4 requires exportin 1, also
known as CRM1, and a nuclear export sequence near the Smad4
linker region [114,115]. The oncogene product v-ErbA can interact
with Smad4 and sequester it in the cytoplasm, which results in
attenuated TGF-b responsiveness and growth inhibition, and thus
contributes to the oncogenicity of v-ErbA [116].
In addition to constitutive phosphorylation, Smad4 is also regu-
lated by signal-dependent phosphorylation [39]. The kinase LKB1
can phosphorylate Smad4 in its MH1 domain, thus interfering with
Smad4 binding to DNA, and inhibiting Smad-mediated gene
expression [117]. Erk MAPK can phosphorylate Smad4 at a se-
quence in the linker region that stabilizes the binding of the co-
activators p300 and CBP with the heteromeric Smad complex. This
phosphorylation may enhance Smad-mediated transcription [118].
The serine/threonine kinase MPK38 can also phosphorylate Smad4,
and this phosphorylation is thought to contribute to enhanced
TGF-b signaling induced by MPK38 [77].
Similarly to Smad2 and Smad3, ADP-ribosylation of the DNA-
binding MH1 domain of Smad4 by PARP-1 interferes with the
DNA binding of Smad4, resulting in attenuated Smad-mediated
transcription [98]. Smad4 can also be sumoylated in its MH1
domain by the E3 ligase PIAS1. Smad4 sumoylation may prevent
Smad4 ubiquitylation, thus protecting Smad4 from degradation,
and enhances TGF-b-induced Smad signaling [119–121]. However,
Smad4 sumoylation was also reported to repress Smad-mediated
transcription by recruiting Daxx to the sumoylated form of Smad4
at regulatory promoter sequences [122].Like R-Smads, Smad4 is targeted by poly-ubiquitylation, leading
to degradation. While Smad4 degradation is mediated by the E3 li-
gases JAB1/CSN5 [123] and SCFb-TrCP1 [124], some Smad4 mutants
found in cancers are targeted for SCFskp2-mediated ubiquitylation
[125].
Ectodermin, identiﬁed in Xenopus embryos, was shown to func-
tion as E3 ubiquitin ligase for Smad4 that drives Smad4 degrada-
tion and thus inhibits TGF-b signaling [126]. Conﬂicting ﬁndings
showed that this same protein, identiﬁed as TIF1c and later re-
named TRIM33, associates with TGF-b-activated Smad2/3 in com-
petition with Smad4, and directs Smad4-independent transcription
that regulates erythriod differentiation [127]. Ectodermin/TIF1c
was also shown to mono-ubiquitylate Smad4 in its MH2 domain,
thus interfering with Smad4 association with activated Smad2/3
[128]. Furthermore, the PHD ﬁnger-bromodomain of TIF1c consti-
tutes a histone-binding module that speciﬁcally interacts with his-
tone H3, and Smad4 ubiquitylation by TIF1c requires this domain,
and is induced by TIF1c binding to histone [129]. The PHD-Bromo
domain of TIF1c/TRIM33 also facilitates binding of TRIM33-
Smad2/3 to H3K9me3 and H3K18ac on the promoters of mesendo-
derm regulators, thus displacing the chromatin-compacting factor
HP1c, and making Nodal response elements accessible to Smad4-
Smad2/3 for later RNA polymerase II recruitment. Thus, Smad
complexes use TIF1c and the H3K9me3 mark as platform to trigger
differentiation of mammalian embryonic stem cells [130]. Despite
their complexity, these ﬁndings all support the notion that, ecto-
dermin/TIF1c/TRIM33 antagonizes the transcription coactivator
role of Smad4.
In contrast to the inhibitory effects of K519 mono-ubiquityla-
tion by ectodermin [128], Smad4 mono-ubiquitylation at K507 en-
hanced the capacity of Smad4 to form complexes with activated R-
Smads [131]. Ubiquitylation-mediated degradation of Smad4 can
be antagonized by de-ubiquitylases. Thus, the de-ubiquitylase
FAM/USP9 can remove K519 mono-ubiquitylation of Smad4
imposed by TIF1c, and thus restore Smad4 function [128].
In summary, like Smad2 and Smad3, the function and stability
of Smad4 are extensively post-translationally regulated, thus pro-
viding high versatility to TGF-b/Smad signaling (Fig. 2).
16. Regulation of TGF-b-induced Smad signaling by inhibitory
Smad7
In vertebrates, two inhibitory Smads, Smad6 and Smad7, inhibit
Smad activation by binding to the activated type I receptor, thus
interfering with R-Smad binding and activation. Smad6 preferen-
tially inhibits BMP signaling through Smad1/5, and Smad7 inhibits
both TGF-b/activin and BMP-induced R-Smad activation [132].
Focusing on TGF-b signaling, Smad7 binds to activated TbRI, inter-
fering with TGF-b-induced Smad2/3 activation [133], yet is also
instrumental in attenuating the TGF-b receptors. Indeed, Smad7
binding to TbRI can recruit E3 ubiquitin ligases such as Smurf2
[45] or WWP1 [48] to the receptor complex, leading to TbRI ubiq-
uitylation and degradation [45,48], or the GADD34-PP1c phospha-
tase complex, whichmay play a role in terminating TGF-b signaling
through dephosphorylation of the activated TbRI [40]. Remarkably,
Smad7 also acts as adaptor required for TGF-b-induced activation
of p38 MAPK signaling [134]. In the nucleus, Smad7 may antago-
nize TGF-b/Smad-mediated transcription by interfering with func-
tional Smad-DNA complex formation [135], and was shown to
associate with MyoD and promote myogenic differentiation
[136]. Continuously shuttling between nucleus and cytoplasm
enables Smad7 to provide negative feedback in the control of
TGF-b signaling in multiple compartments (Fig. 2) [65].
Many signaling pathways activate Smad7 expression and thus
lead to attenuation of TGF-b signaling. Consistent with its role as
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though Smad3/4 binding to its promoter [8]. Additionally, activa-
tion of ERK, JNK or p38 MAPK all result in transcriptional activation
of Smad7 expression, thus dampening TGF-b signaling [137]. Sim-
ilarly, cytokines, such as IFN-c or IL-7, can induce Smad7 expres-
sion through activation of Jak/STAT signaling [138,139]. Likewise,
TNF-a induces Smad7 expression through NF-jB, thus inhibiting
TGF-b/Smad-mediated responses [140]. Hypoxia also activates
Smad7 expression, which is mediated by the transcription factor
HIF1a and contributes to malignant cell invasiveness [141].
Smad7 expression is additionally regulated by miRNAs, speciﬁ-
cally miR-106b-25 and miR-21, resulting in decreased Smad7
expression and increased TGF-b signaling [142,143]. However,
TGF-b can directly induce miR-21 expression through R-Smad acti-
vation. Thus, miR-21-mediated decrease of Smad7 expression
could counteract Smad7-mediated negative feedback mechanisms
of TGF-b signaling, and allow prolonged TGF-b effects, as proposed
in the induction of ﬁbrosis [143].
Smad7 protein levels are also controlled by ubiquitylation, e.g.
by the E3 ligases Smurf1 and WWP1, and degradation [87]. Fur-
thermore, through its association with Axin, Smad7 is ubiquitylat-
ed by Arkadia [144,145], and the resulting Smad7 degradation
decreases the feedback inhibition of TGF-b signaling, resulting in
increased TGF-b signaling, which may contribute to atrial ﬁbrilla-
tion-induced atrial ﬁbrosis [146]. The role of Arkadia in Smad7
degradation and enhanced TGF-b signaling may provide a basis
for its tumor suppressor properties in colorectal cancer [147].
The deubiquitylating enzyme CYLD additionally inhibits TGF-b sig-
naling by forming a complex with Smad7 and facilitates its deub-
iquitylation at two sites in its MH2 domain [148].
Finally, the function of Smad7 is regulated by acetylation. The
interaction of Smad7 with the transcription coactivator p300 leads
to direct Smad7 acetylation on two lysines close to the N-terminus
[149]. As these residues are also targeted by ubiquitylation, their
acetylation prevents Smad7 ubiquitylation by Smurf1 and subse-
quent degradation [149]. Conversely, the histone deacetylases
HDAC1 and SIRT1 are able to interact with the N-terminus of
Smad7 and reverse acetylation, thus enhancing Smurf1-mediated
ubiquitylation and proteasomal degradation of Smad7 [150,151].
The competition between ubiquitylation and acetylation likely reg-
ulate Smad7 stability inside nucleus.
17. Regulation through Smad transcriptional crosstalk
In the nucleus, the activated Smad complexes orchestrate
changes in transcription of target genes through cooperation with
sequence-speciﬁc, DNA-binding transcription factors at conducive
Smad binding sites. These transcription complexes coopt transcrip-
tion coactivators and/or corepressors to deﬁne the amplitude of
the transcription activation or repression, modify the local chroma-
tin structure and engage the basal transcription machinery [9,10].
In this way, TGF-b directly induces Smad-mediated transcription
activation or repression of several hundreds of genes, dependent
on the physiological context [152]. Intrinsic in this mechanism of
Smad-mediated transcription is the cooperation with, and depen-
dence on, a large and diverse set of DNA binding transcription fac-
tors that not only deﬁne the target regulatory DNA sequences of
Smad cooperation, but are themselves extensively regulated by
signaling pathways. These transcription complexes therefore
intrinsically serve as excellent platforms for functional crosstalk
between TGF-b/Smad signaling and other pathways. The complex-
ity and versatility of transcription regulation of Smads, and the
many opportunities for signaling crosstalk at the level of nucleo-
protein transcription complexes have been reviewed [2,9,10,137],
but will be illustrated with a few examples of signaling crosstalk.TGF-b/Smad signaling extensively cooperates with Wnt signal-
ing, and such crosstalk occurs at multiple levels, including induc-
tion of TGF-b ligand expression [137], and interactions of TGF-b
receptors or Smads with Axin or GSK3 [74,145,153], as mentioned.
In the nucleoprotein transcription complexes, activated Smads
were found to directly associate and cooperate with TCF and LEF,
two DNA-binding transcription factors that serve as effectors of
Wnt-induced transcription responses, and to transcriptionally reg-
ulate diverseWnt target genes [154,155]. Smad also form transcrip-
tion complexeswith b-catenin and their association is thought to be
stabilized by p300/CBP coactivator [155]. For example, in mesen-
chymal stem cells, TGF-b induces a fast co-translocation of Smad3
and b-catenin into the nucleus, to then cooperatively regulate a
set of genes that cannot be recognized by either Smads or b-catenin
alone [156].
Cooperating with Notch signaling, TGF-b-activated Smad3 com-
plexes associate directly with the Notch intracellular domain
(NICD) and the DNA-binding transcription factor CSL to regulate
transcription of the gene encoding Hes-1, a Notch signaling target
gene [157]. Conceptually similarly, activated Smad3 associated
with NICD to cooperatively activate the Foxp3 expression in mur-
ine regulatory T cells [158]. However, NICD also promotes cell
growth and cancer development by suppressing the growth inhib-
itory effects of TGF-b by sequestering p300 from activated Smad3
[159].
Smads also crosstalk with MAPK pathways at multiple levels. In
addition to activating the expression of TGF-b ligands and the
inhibitory Smad7, MAPKs phosphorylate R-Smads and Smad4 at
multiple sites, further deﬁning their activities and stabilities
[137]. At the level of transcription regulation by Smads, MAPKs tar-
get various transcription factors that associate with Smads and
enable Smads to cooperatively orchestrate gene expression re-
sponses. Among these, Smads associate and cooperate with c-Jun,
Jun-B, c-Fos and other AP-1 transcription factors. Indeed, TGF-b-in-
duced transcription activation of many genes is thought to result
from crosstalk with MAPK signaling, and often occurs through
cooperation of Smads with AP-1 complexes [160–163]. As another
example, TGF-b directly induces, through Smad3/4, expression of
the transcription factor ATF3, which then cooperates with Smad3
in ATF3-mediated secondary gene expression responses. As target
of both TGF-b signaling and p38 MAPK stress signaling, ATF3 inte-
grates both pathways in the response of epithelial cells to stress
and injury [164].
In summary, Smad-mediated transcription through interactions
with many types of transcription factors allow extensive versatil-
ity, dependent upon activation of other signaling pathways.
18. Concluding remarks
TGF-b family signaling through Smads is conceptually a simple
and linear signaling pathway, driven by sequential phosphoryla-
tion, with the type II receptors activating the type I receptors,
which in turn activate R-Smads. However, as we dissect the com-
plexities of the TGF-b responses and their context-dependence,
we have come to appreciate its amazing versatility and regulation.
Heteromeric combinations of type II and type I receptors, and of
activated Smads provide levels of versatility that accommodate
the many ligands and complex signaling patterns and cellular re-
sponses [9,10,65]. As illustrated in this review, many levels of
post-translational regulation of the receptors and Smads deﬁne
receptor and Smad stability, provide negative feedback mecha-
nisms, and help deﬁne their functions, thus providing insight into
the exquisite regulation of the complex responses (Figs. 1 and 2).
Protein interactions with the receptors and Smads further help de-
ﬁne their functions and are required for the many phases in their
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sponses. Finally, illustrated with some examples, functional cross-
talk of TGF-b/Smad signaling with other pathways explains the
context-dependence of the TGF-b response, depending on the
physiological state of the cells. In fact, Smad-mediated transcrip-
tion complexes intrinsically depend on cooperation with DNA-
binding transcription factors and coregulators that are themselves
also targets of many other pathways.
Going forward, further characterization of the regulation and
roles of post-translational modiﬁcations and protein interactions
in TGF-b/Smad signaling will provide exciting insights into how
such conceptually simple signaling system can give rise to exqui-
site versatility and complexity. More richness to our understanding
will be unraveled from the use of efﬁcient and sensitive mass spec-
trometry methods, systems approaches using CHIP-seq, deep RNA
sequencing techniques, and bioinformatics, in combination with
detailed mechanistic studies.
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